Stemline Therapeutics Inc. (STML)

17.75
NASDAQ : Health Technology
Prev Close 17.60
Day Low/High 17.15 / 17.80
52 Wk Low/High 6.40 / 18.00
Avg Volume 264.90K
Exchange NASDAQ
Shares Outstanding 29.53M
Market Cap 488.67M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Buy Stemline Therapeutics At $10, Earn 16.4% Annualized Using Options

Investors considering a purchase of Stemline Therapeutics Inc shares, but tentative about paying the going market price of $13.57/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June put at the $10 strike, which has a bid at the time of this writing of 70 cents.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc. - STML

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc. - STML

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc.

Stemline Therapeutics Stock Sees Short Interest Drop 17%

Stemline Therapeutics Stock Sees Short Interest Drop 17%

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 257,298 share decrease in total short interest for Stemline Therapeutics Inc , to 1,266,636, a decrease of 16.88% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Stemline Therapeutics Becomes Oversold (STML)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of STML August 18th Options Trading

Investors in Stemline Therapeutics Inc saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the STML options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed A Complaint To Recover Losses Suffered By Investors In Stemline Therapeutics, Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Stemline Therapeutics, Inc.

TheStreet Quant Rating: D (Sell)